Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.

ABSTRACT:

Importance

Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible.

Objective

To investigate whether dose reduction (DR) of biologics in patients with stable psoriasis is noninferior to usual care (UC).

Design, setting, and participants

This pragmatic, open-label, prospective, controlled, noninferiority randomized clinical trial was conducted from March 1, 2016, to July 22, 2018, at 6 dermatology departments in the Netherlands. A total of 120 patients with plaque psoriasis and stable low disease activity who were receiving treatment with adalimumab, etanercept, or ustekinumab were studied.

Interventions

Patients were randomized 1:1 to DR (n = 60) or UC (n = 60). In the DR group, injection inter

SUBMITTER: Atalay S 

PROVIDER: S-EPMC7042801 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature